NCT05800366 2026-03-05A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaDana-Farber Cancer InstitutePhase 2 Recruiting41 enrolled
NCT05410418 2025-12-15Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular LymphomaWashington University School of MedicinePhase 2 Active not recruiting34 enrolled